AIxCrypto Holdings, Inc.
AIXC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AIXC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AIXC
AIxCrypto Holdings, Inc. (AIXC) is a biotechnology company focused on developing therapeutic drug candidates, currently in a capital-constrained phase with no approved products and a strategic review of its pipeline underway.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for AIxCrypto Holdings, Inc..
AIxCrypto Holdings, Inc. (AIXC) is a biotechnology company focused on developing therapeutic drug candidates, currently in a capital-constrained phase with no approved products and a strategic review of its pipeline underway.
- Cash and equivalents were $0.6M as of 2026-06-30, with net income of -$4.2M and shareholders' equity of $28.0M [sec].
- The company has an accumulated deficit of $140.0M as of December 31, 2025 [sec_mda · as of 2026-03-30].
- AIXC has slowed development of its therapeutic products beginning in the second quarter 2024 and implemented expense controls to stem losses [sec_mda · as of 2025-06-30].
- The company faces a going concern uncertainty and is in arrears on accounts payable to important partners [sec_mda · as of 2026-03-30].
- AIXC has obligations under license agreements for milestone payments tied to development, regulatory, and commercial achievements [sec_mda · as of 2026-05-11].
What works
- The company has no material contractual obligations beyond those disclosed, providing some financial flexibility [sec_mda · as of 2026-05-11].
- Management and the board are strategically reviewing plans to advance the therapeutics pipeline, with potential to ramp up development when properly funded [sec_mda · as of 2025-06-30].
What to weigh
- The company has incurred recurring losses and expects to continue to incur losses, with an accumulated deficit of $140.0M as of December 31, 2025 [sec_mda · as of 2026-03-30].
- Cash position is very low at $0.6M as of 2026-06-30, and the company is in arrears on accounts payable to important partners [sec_mda · as of 2026-03-30].
- Development of therapeutic products has been slowed since Q2 2024 due to financial constraints, and the company's ability to continue as a going concern is uncertain [sec_mda · as of 2025-06-30].
- The company faces risks in raising sufficient working capital to complete development and launch of drug candidates [sec_mda · as of 2025-11-14].
From the filings
Quoted directly from source documents.
The company has a very low cash position and significant accumulated deficit.
“As of December 31, 2025, we had approximately $19.3 million in cash and accounts payable of $1.3 million. We are in arrears on accounts payable to important partners. We have incurred recurring losses from operations and have an accumulated deficit of $140.0 million at December 31, 2025.”
SEC MD&A · March 30, 2026
The company slowed development of therapeutic products due to financial situation.
“Given our financial situation, the company slowed the development of the aforementioned therapeutic products beginning in the second quarter 2024.”
SEC MD&A · June 30, 2025
The company has obligations under license agreements for milestone payments.
“We have obligations under various license agreements to make future payments to third parties that become due and payable on the achievement of certain development, regulatory and commercial milestones (such as the start of a clinical trial, filing for product approval with the FDA or other regulatory agencies, product approval by the FDA or other regulatory agencies, product launch or product sales) or on the sublicense of our rights to another party.”
SEC MD&A · May 11, 2026
The company faces risks in raising sufficient working capital.
“our ability to procure sufficient working capital to continue and complete the development, testing and launch of our prospective drug products;”
SEC MD&A · November 14, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company's financial statements are prepared assuming it will continue as a going concern, but it has weak liquidity and recurring losses [sec_mda · as of 2026-03-30].
- Cash runway and liquidity — Cash of $0.6M as of 2026-06-30 is very low, and the company is in arrears on accounts payable to partners [sec_mda · as of 2026-03-30].
- Development pipeline halted — Therapeutic product development has been slowed since Q2 2024 due to financial constraints, with no clear timeline for resumption [sec_mda · as of 2025-06-30].
- Milestone payment obligations — License agreements require future payments upon achieving development or regulatory milestones, adding financial pressure if triggered [sec_mda · as of 2026-05-11].
What to watch
- Ability to raise additional capital through capital markets or strategic partnerships to fund pipeline development [sec_mda · as of 2025-06-30].
- Outcome of management's strategic review of how to advance the therapeutics pipeline [sec_mda · as of 2025-06-30].
- Any updates on the company's ability to maintain its Nasdaq listing [sec_mda · as of 2026-05-11].
- Progress on resolving arrears with accounts payable to important partners [sec_mda · as of 2026-03-30].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run AIxCrypto Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AIxCrypto Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
2.0 months
D/E 0.30 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$156K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 70,478 | $88K |
| vanguard capital management llc | 28,720 | $36K |
| two sigma securities, llc | 13,539 | $17K |
| goldman sachs group inc | 10,791 | $13K |
| blackrock, inc. | 501 | $626 |
| harbour investments, inc. | 325 | $406 |
| highmark wealth management llc | 160 | $200 |
| group one trading llc | 8 | $10 |
| physician wealth advisors, inc. | 2 | $3 |
| danske bank a/s | 1 | $1 |
Showing top 10 of 11 institutional holders of AIxCrypto Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.4%
- Days to cover
- 1.7
- Shares short
- 87,806
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AIXC short interestGovernance
Frequently asked questions
What is the AI investment thesis for AIxCrypto Holdings, Inc.?
AIxCrypto Holdings, Inc. (AIXC) is a biotechnology company focused on developing therapeutic drug candidates, currently in a capital-constrained phase with no approved products and a strategic review of its pipeline underway.
What is AIxCrypto Holdings, Inc.'s lead drug candidate?
AIxCrypto Holdings, Inc.'s most advanced tracked candidate is pan-ras (Preclinical) for pancreatic, colorectal and lung cancers.
Who is the CEO of AIxCrypto Holdings, Inc.?
Mr. Jiawei Wang is the chief executive officer of AIxCrypto Holdings, Inc. (AIXC).
Where is AIxCrypto Holdings, Inc. headquartered?
AIxCrypto Holdings, Inc. (AIXC) is headquartered in El Segundo, CA, United States.
What therapeutic areas does AIxCrypto Holdings, Inc. focus on?
AIxCrypto Holdings, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.